RESUMEN
The installation of aldehydes into synthetic protein ligands is an efficient strategy to engage protein lysine residues in remarkably stable imine bonds and augment the compound affinity and selectivity for their biological targets. The high frequency of lysine residues in proteins and the reversibility of the covalent ligand-protein bond support the application of aldehyde-bearing ligands, holding promises for their future use as drugs. This review highlights the increasing exploitation of salicylaldehyde modules in various classes of protein binders, aimed at the reversible-covalent engagement of lysine residues.
Asunto(s)
Aldehídos , Lisina , Lisina/química , Aldehídos/química , Proteínas , Iminas , LigandosRESUMEN
Self-immolative (SI) spacers are degradable chemical connectors widely used in prodrugs and drug conjugates to release pharmaceutical ingredients in response to specific stimuli. Amine-carbamate SI spacers are particularly versatile, as they have been used to release different hydroxy cargos, ranging from 2° and 3° alcohols to phenols and oximes. In this work, we describe the ability of three amine-carbamate SI spacers to release three structurally similar imidazoquinoline payloads, bearing either a 1°, a 2° or a 3° alcohol as the leaving group. While the spacers showed comparable efficacy at releasing the 2° and 3° alcohols, the liberation of the 1° alcohol was much slower, unveiling a counterintuitive trend in nucleophilic acyl substitutions. The release of the 1° alcohol payload was only possible using a SI spacer bearing a pyrrolidine ring and a tertiary amine handle, which opens the way to future applications in drug delivery systems.
Asunto(s)
Aminas , Profármacos , Carbamatos , Sistemas de Liberación de Medicamentos , EtanolRESUMEN
Herein, we report the synthesis and characterization of several chiral (cyclopentadienone)iron complexes (CICs) featuring either two (R)-BINOL-derived stereoaxes or a combination of one (R)-BINOL-derived stereoaxis and a stereogenic plane. The stereoplane-containing CICs were obtained as epimer mixtures, which were separated by flash column chromatography and assigned an absolute configuration based on XRD analysis, NMR and order of elution. The library was tested in the asymmetric hydrogenation of ketones showing good catalytic activity and a moderate stereoselectivity which, notably, is mostly imparted by the stereogenic plane. Indeed, the two epimers of each CIC possessing a stereoplane show opposite and equally strong stereochemical preference.
RESUMEN
Salicylaldehyde (SA) derivatives are emerging as useful fragments to obtain reversible-covalent inhibitors interacting with the lysine residues of the target protein. Here the SA installation at the C terminus of an integrin-binding cyclopeptide, leading to enhanced ligand affinity for the receptor as well as stronger biological activity in cultured glioblastoma cells is reported.
Asunto(s)
Integrinas , Lisina , Integrinas/metabolismo , Adhesión Celular , Péptidos Cíclicos/química , Oligopéptidos/químicaRESUMEN
Herein, we investigate the use of organic photocatalysts in the visible light-promoted ß-functionalization of carbonyl compounds. In particular, we studied the addition of aliphatic aldehydes to α,ß-unsaturated compounds (ß-Michael addition), and the reaction of cyclic ketones with either ketones (ß-aldol condensation) or imines (ß-Mannich reaction). Among the dyes tested, donor-acceptor cyanoarenes gave the best results, promoting the transformations of interest in moderate to good yields. The reaction scope was investigated on substrates with different steric and electronic properties. Fluorescence quenching analysis (Stern-Volmer experiments) led us to propose for these reactions a reductive quenching mechanism involving a transient 5πe- activation mode.
RESUMEN
Alzheimer's disease is the most common type of dementia, affecting millions of people worldwide. One of its main consequences is memory loss, which is related to downstream effectors of cyclic adenosine monophosphate (cAMP). A well-established strategy to avoid cAMP degradation is the inhibition of phosphodiesterase (PDE). In recent years, GEBR-32a has been shown to possess selective inhibitory properties against PDE type 4 family members, resulting in an improvement in spatial memory processes without the typical side effects that are usually correlated with this mechanism of action. In this work, we performed the HPLC chiral resolution and absolute configuration assignment of GEBR-32a. We developed an efficient analytical and semipreparative chromatographic method exploiting an amylose-based stationary phase, we studied the chiroptical properties of both enantiomers and we assigned their absolute configuration by 1H-NMR (nuclear magnetic resonance). Lastly, we measured the IC50 values of both enantiomers against both the PDE4D catalytic domain and the long PDE4D3 isoform. Results strongly support the notion that GEBR-32a inhibits the PDE4D enzyme by interacting with both the catalytic pocket and the regulatory domains.
Asunto(s)
Fosfodiesterasas de Nucleótidos Cíclicos Tipo 4/química , Inhibidores de Fosfodiesterasa 4/química , Humanos , Resonancia Magnética Nuclear BiomolecularRESUMEN
Self-immolative (SI) spacers are sophisticated chemical constructs designed for molecular delivery or material degradation. We describe herein a (S)-2-(aminomethyl)pyrrolidine SI spacer that is able to release different types of anticancer drugs (possessing either a phenolic or secondary and tertiary hydroxyl groups) through a fast cyclization mechanism involving carbamate cleavage. The high efficiency of drug release obtained with this spacer was found to be beneficial for the inâ vitro cytotoxic activity of protease-sensitive prodrugs, compared with a commonly used spacer of the same class. These findings expand the repertoire of degradation machineries and are instrumental for the future development of highly efficient delivery platforms.
Asunto(s)
Antineoplásicos/farmacología , Carbamatos/farmacología , Profármacos/farmacología , Prolina/farmacología , Antineoplásicos/síntesis química , Antineoplásicos/química , Carbamatos/síntesis química , Carbamatos/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ciclización , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Estructura Molecular , Profármacos/síntesis química , Profármacos/química , Prolina/síntesis química , Prolina/químicaRESUMEN
The covalent conjugation of potent cytotoxic agents to either macromolecular carriers or small molecules represents a well-known approach to increase the therapeutic index of these drugs, thus improving treatment efficacy and minimizing side effects. In general, cytotoxic activity is displayed only upon cleavage of a specific chemical bond (linker) that connects the drug to the carrier. The perfect balance between the linker stability and its selective cleavage represents the key for success in these therapeutic approaches and the chemical toolbox to reach this goal is continuously expanding. In this Review article, we highlight recent advances on the different modalities to promote the selective release of cytotoxic agents, either by exploiting specific hallmarks of the tumor microenvironment (e.g. pH, enzyme expression) or by the application of external triggers (e.g. light and bioorthogonal reactions).
Asunto(s)
Antineoplásicos/química , Portadores de Fármacos/química , Neoplasias/tratamiento farmacológico , Antineoplásicos/metabolismo , Antineoplásicos/uso terapéutico , Liberación de Fármacos , Enzimas/metabolismo , Humanos , Hidrólisis , Rayos Infrarrojos , Neoplasias/patología , Microambiente TumoralRESUMEN
This work takes advantage of one of the hallmarks of cancer, that is, the presence of tumor infiltrating cells of the immune system and leukocyte-secreted enzymes, to promote the activation of an anticancer drug at the tumor site. The peptidomimetic integrin ligand cyclo(DKP-RGD) was found to accumulate on the surface of αv ß3 integrin-expressing human renal cell carcinoma 786-O cells. The ligand was conjugated to the anticancer drug paclitaxel through a Asn-Pro-Val (NPV) tripeptide linker, which is a substrate of neutrophil-secreted elastase. Inâ vitro linker cleavage assays and cell antiproliferative experiments demonstrate the efficacy of this tumor-targeting conjugate, opening the way to potential therapeutic applications.
Asunto(s)
Antineoplásicos Fitogénicos/metabolismo , Integrina alfaVbeta3/metabolismo , Elastasa de Leucocito/metabolismo , Paclitaxel/metabolismo , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Liberación de Fármacos , Humanos , Integrina alfaVbeta3/genética , Ligandos , Microscopía Confocal , Oligopéptidos/química , Paclitaxel/química , Paclitaxel/farmacología , Vitronectina/química , Vitronectina/metabolismoRESUMEN
A C2-symmetric bicyclic peptide bearing two RGD motifs was developed as a dimeric ligand, and it displayed enhanced inhibition of ECM protein binding to purified integrin receptors as compared to monomeric RGD analogues. Moreover, the dimeric bicyclic ligand induced cell detachment and inhibited FAK phosphorylation in U-373 MG glioblastoma cells.
Asunto(s)
Proteínas de la Matriz Extracelular/antagonistas & inhibidores , Glioblastoma/tratamiento farmacológico , Integrinas/química , Oligopéptidos/química , Sitios de Unión/efectos de los fármacos , Adhesión Celular/efectos de los fármacos , Línea Celular Tumoral , Dimerización , Proteínas de la Matriz Extracelular/química , Quinasa 1 de Adhesión Focal/antagonistas & inhibidores , Quinasa 1 de Adhesión Focal/metabolismo , Glioblastoma/metabolismo , Glioblastoma/patología , Humanos , Ligandos , Péptidos Cíclicos/síntesis química , Péptidos Cíclicos/química , Fosforilación/efectos de los fármacosRESUMEN
A non-internalizing αvß3 integrin ligand was conjugated to the anticancer drug MMAE through a ß-glucuronidase-responsive linker. In the presence of ß-glucuronidase, only the conjugate bearing a PEG4 spacer inhibited the proliferation of integrin-expressing cancer cells at low nanomolar concentrations, indicating important structural requirements for the efficacy of these therapeutics.
Asunto(s)
Antineoplásicos/farmacología , Glioblastoma/tratamiento farmacológico , Integrina alfaVbeta3/antagonistas & inhibidores , Oligopéptidos/farmacología , Antineoplásicos/síntesis química , Antineoplásicos/química , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayos de Selección de Medicamentos Antitumorales , Glioblastoma/metabolismo , Glioblastoma/patología , Glucuronidasa , Humanos , Integrina alfaVbeta3/química , Integrina alfaVbeta3/metabolismo , Ligandos , Conformación Molecular , Oligopéptidos/síntesis química , Oligopéptidos/química , Relación Estructura-Actividad , Vitronectina/antagonistas & inhibidores , Vitronectina/química , Vitronectina/metabolismoRESUMEN
RGD-α-amanitin and isoDGR-α-amanitin conjugates were synthesized by joining integrin ligands to α-amanitin via various linkers and spacers. The conjugates were evaluated for their ability to inhibit biotinylated vitronectin binding to the purified αVß3 receptor, retaining good binding affinity, in the same nanomolar range as the free ligands. The antiproliferative activity of the conjugates was evaluated in three cell lines possessing different levels of αVß3 integrin expression: human glioblastoma U87 (αVß3+), human lung carcinoma A549 (αVß3-) and breast adenocarcinoma MDA-MB-468 (αVß3-). In the U87, in the MDA-MB-468, and partly in the A549 cancer cell lines, the cyclo[DKP-isoDGR]-α-amanitin conjugates bearing the lysosomally cleavable Val-Ala linker were found to be slightly more potent than α-amanitin. Apparently, for all these α-amanitin conjugates there is no correlation between the cytotoxicity and the expression of αVß3 integrin. To determine whether the increased cytotoxicity of the cyclo[DKP-isoDGR]-α-amanitin conjugates is governed by an integrin-mediated binding and internalization process, competition experiments were carried out in which the conjugates were tested with U87 (αVß3+, αVß5+, αVß6-, α5ß1+) and MDA-MB-468 (αVß3-, αVß5+, αVß6+, α5ß1-) cells in the presence of excess cilengitide, with the aim of blocking integrins on the cell surface. Using the MDA-MB-468 cell line, a fivefold increase of the IC50 was observed for the conjugates in the presence of excess cilengitide, which is known to strongly bind not only αVß3, but also αVß5, αVß6, and α5ß1. These data indicate that in this case the cyclo[DKP-isoDGR]-α-amanitin conjugates are possibly internalized by a process mediated by integrins different from αVß3 (e.g., αVß5).
RESUMEN
This work reports the synthesis of three multimeric RGD peptidomimetic-paclitaxel conjugates featuring a number of αV ß3 integrin ligands ranging from 2 to 4. These constructs were assembled by conjugation of the integrin αV ß3 ligand cyclo[DKP-RGD]-CH2 NH2 with paclitaxel via a 2'-carbamate with a self-immolative spacer, the lysosomally cleavable Val-Ala dipeptide linker, a multimeric scaffold, a triazole linkage, and finally a PEG spacer. Two monomeric conjugates were also synthesized as reference compounds. Remarkably, the new multimeric conjugates showed a binding affinity for the purified integrin αV ß3 receptor that increased with the number of integrin ligands (reaching a minimum IC50 value of 1.2â nm for the trimeric), thus demonstrating that multivalency is an effective strategy to strengthen the ligand-target interactions.
Asunto(s)
Integrina alfaVbeta3/metabolismo , Oligopéptidos/química , Paclitaxel/química , Peptidomiméticos/química , Biotinilación , Concentración 50 Inhibidora , Integrina alfaVbeta3/química , Peptidomiméticos/metabolismo , Unión Proteica , Vitronectina/química , Vitronectina/metabolismoRESUMEN
Herein we report the first example of an isoDGR-drug conjugate (2), designed to release paclitaxel selectively within cancer cells expressing integrin αV ß3 . Conjugate 2 was synthesized by connecting the isoDGR peptidomimetic 5 with paclitaxel via the lysosomally cleavable Val-Ala dipeptide linker. Conjugate 2 displayed a low nanomolar affinity for the purified integrin αV ß3 receptor (IC50 =11.0â nm). The tumor targeting ability of conjugate 2 was assessed in vitro in anti-proliferative assays on two isogenic cancer cell lines characterized by different integrin αV ß3 expression: human glioblastoma U87 (αV ß3 +) and U87 ß3 -KO (αV ß3 -). The isoDGR-PTX conjugate 2 displayed a remarkable targeting index (TI=9.9), especially when compared to the strictly related RGD-PTX conjugate 4 (TI=2.4).
Asunto(s)
Oligopéptidos/química , Paclitaxel/química , Secuencia de Aminoácidos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Humanos , Concentración 50 Inhibidora , Integrina alfaVbeta3/antagonistas & inhibidores , Integrina alfaVbeta3/genética , Integrina alfaVbeta3/metabolismo , Peptidomiméticos/química , Peptidomiméticos/toxicidadRESUMEN
(Cyclopentadienone)iron complexes have recently gained widespread interest as cheap metal-based pre-catalysts for the reduction of carbonyl compounds and imines, thanks to their air- and moisture-stability and easy synthesis/purification. In this account, several approaches are presented to achieve enantioselective C=O and C=N bond reduction using this class of iron complexes. Most of the examples, used in the asymmetric reduction of ketones, rely on chiral (cyclopentadienone)iron complexes, featuring a chiral cyclopentadienone backbone and/or a chiral monophosphoramidite ligand, introduced by replacement of a CO ligand. The enantiomeric excesses achieved so far with this strategy are at best moderate. Better ees could be obtained with an alternative approach, used in the enantioselective reduction of C=N bonds, which consists in combining an achiral (hydroxycyclopentadienyl)iron complex (i.e. the activated form of a (cyclopentadienone)iron complex) with a chiral phosphoric acid.
RESUMEN
The use of an equivalent amount of an organic base leads to high enantiomeric excess in the asymmetric hydrogenation of N-benzylated 3-substituted pyridinium salts into the corresponding piperidines. Indeed, in the presence of Et3 N, a Rh-JosiPhos catalyst reduced a range of pyridinium salts with ee values up to 90 %. The role of the base was elucidated with a mechanistic study involving the isolation of the various reaction intermediates and isotopic labeling experiments. Additionally, this study provided some evidence for an enantiodetermining step involving a dihydropyridine intermediate.
RESUMEN
The rediscovery of chiral monodentate ligands made in the period 1999-2003 had important consequences in enantioselective transition-metal catalysis, such as the introduction of the A/B concept (i.e., use of monodentate ligand mixtures) and, later, a renewed interest in supramolecular ligands capable of ligand-ligand and ligand-substrate interactions. This Personal Account summarizes the contributions made by our research group in this area in the period 2004-2015, which reflect the abovementioned developments. Within this area, we introduced some original concepts, such as 1) the use of chiral tropos ligand mixtures; 2) the development of new strategies to maximize heterocomplex formation from combinations of simple monodentate ligands; 3) the investigation of new ligand-ligand interactions to achieve selective heterocomplex formation; and 4) the development of highly efficient and synthetically accessible supramolecular ligands.
RESUMEN
The cyclo[DKP-isoDGR] peptidomimetics 2-5, containing bifunctional diketopiperazine (DKP) scaffolds that differ in the configuration of the two DKP stereocenters and in the substitution at the DKP nitrogen atoms, were prepared and examined in vitro in competitive binding assays with purified αv ß3 and αv ß5 integrin receptors. IC50 values ranged from low nanomolar (ligand 3) to submicromolar with αv ß3 integrin. The biological activities of ligands cyclo[DKP3-RGD] 1 and cyclo[DKP3-isoDGR] 3, bearing the same bifunctional DKP scaffold and showing similar αV ß3 integrin binding values, were compared in terms of their cellular effects in human U373 glioblastoma cells. Compounds 1 and 3 displayed overlapping inhibitory effects on the FAK/Akt integrin activated transduction pathway and on integrin-mediated cell infiltration processes, and qualify therefore, despite the different RGD and isoDGR sequences, as integrin antagonists. Both compounds induced apoptosis in glioma cells after 72â hour treatment.
Asunto(s)
Antineoplásicos/química , Antineoplásicos/farmacología , Dicetopiperazinas/química , Dicetopiperazinas/farmacología , Glioblastoma/tratamiento farmacológico , Peptidomiméticos/química , Peptidomiméticos/farmacología , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Glioblastoma/metabolismo , Humanos , Integrina alfaVbeta3/metabolismo , Péptidos Cíclicos/química , Péptidos Cíclicos/farmacología , Receptores de Vitronectina/metabolismo , Transducción de Señal/efectos de los fármacosRESUMEN
Two small-molecule-drug conjugates (SMDCs, 6 and 7) featuring lysosomally cleavable linkers (namely the Val-Ala and Phe-Lys peptide sequences) were synthesized by conjugation of the αvß3-integrin ligand cyclo[DKP-RGD]-CH2NH2 (2) to the anticancer drug paclitaxel (PTX). A third cyclo[DKP-RGD]-PTX conjugate with a nonpeptide "uncleavable" linker (8) was also synthesized to be tested as a negative control. These three SMDCs were able to inhibit biotinylated vitronectin binding to the purified αVß3-integrin receptor at nanomolar concentrations and showed good stability at pHâ 7.4 and pHâ 5.5. Cleavage of the two peptide linkers was observed in the presence of lysosomal enzymes, whereas conjugate 8, which possesses a nonpeptide "uncleavable" linker, remained intact under these conditions. The antiproliferative activities of the conjugates were evaluated against two isogenic cell lines expressing the integrin receptor at different levels: the acute lymphoblastic leukemia cell line CCRF-CEM (αVß3-) and its subclone CCRF-CEM αVß3 (αVß3+). Fairly effective integrin targeting was displayed by the cyclo[DKP-RGD]-Val-Ala-PTX conjugate (6), which was found to differentially inhibit proliferation in antigen-positive CCRF-CEM αVß3 versus antigen-negative isogenic CCRF-CEM cells. The total lack of activity displayed by the "uncleavable" cyclo[DKP-RGD]-PTX conjugate (8) clearly demonstrates the importance of the peptide linker for achieving the selective release of the cytotoxic payload.
Asunto(s)
Antineoplásicos/síntesis química , Dicetopiperazinas/química , Lisosomas/química , Oligopéptidos/química , Paclitaxel/análogos & derivados , Péptidos Cíclicos/síntesis química , Peptidomiméticos/síntesis química , Antineoplásicos/química , Antineoplásicos/farmacología , Unión Competitiva , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Liberación de Fármacos , Estabilidad de Medicamentos , Humanos , Integrina alfaVbeta3/metabolismo , Ligandos , Estructura Molecular , Paclitaxel/síntesis química , Paclitaxel/química , Paclitaxel/farmacología , Péptidos Cíclicos/química , Péptidos Cíclicos/farmacología , Peptidomiméticos/química , Peptidomiméticos/farmacologíaRESUMEN
In this study we addressed the role of chirality in the biological activity of RC-33, recently studied by us in its racemic form. An asymmetric synthesis procedure was the first experiment, leading to the desired enantioenriched RC-33 but with an enantiomeric excess (ee) not good enough for supporting the in vitro investigation. An enantioselective high-performance liquid chromatography (HPLC) procedure was then successfully carried out, yielding both RC-33 enantiomers in amounts and optical purity suitable for the pharmacological study. The absolute configuration of pure enantiomers was easily assigned exploiting the asymmetric synthesis previously devised. As emerged in the preliminary in vitro biological investigation, (S)- and (R)-RC-33 possess a comparable affinity towards the σ1 receptor and a very a similar behavior in the calcium influx assay, resulting in an equally effective σ1 receptor agonist. Overall, the results obtained so far suggest that the interaction with the biological target is nonstereoselective and leads us to hypothesize that there is a lack of stereoselectivity in the biological activity of RC-33.